Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research, and Lung Cancer Treatments and Mutations.
Cancer Cell Line Encyclopedia Data Suggest that Ligands for ERBB Family Receptors May Drive <i>BRAF</i> -WT Melanomas
Abstract B065: Using Mutations in a Dimerization Interface of ERBB4 and ERBB2 to Elucidate the Role of ERBB4-ERBB2 Heterodimers in wild-type BRAF Melanomas
Abstract B072: Is targeting ERBB2-ERBB4 heterodimers with monoclonal antibodies effective against wild-type BRAF melanomas?
Abstract 4371: ERBB4 heterodimers appear to drive <i>BRAF</i>WT melanoma cell lines
Human melanoma cell lines that possess wild-type <i>BRAF</i> alleles but are dependent on <i>ERBB4</i> and <i>ERBB2</i>
Recombinant retroviral expression vectors based on pLXSN that encode EGFR, ERBB2, ERBB3, and ERBB4 v1
A recombinant retroviral expression vector (pLXSN-HygR) based on pLXSN that confers resistance to hygromycin and pLXSN-HygR derivatives that encode EGFR, ERBB2, or ERBB3 v1
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines
Abstract 4000: <i>ERBB4</i> is sufficient and necessary for proliferation of <i>BRAF</i> WT melanoma cell lines
<i>ERBB4</i> Mutant Alleles Found in <i>BRAF</i> WT Melanomas That Drive the Proliferation of a <i>BRAF</i> WT Melanoma Cell Line
Abstract 814: Identification of ERBB4 mutant alleles that function as tumor drivers
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
Abstract 5932: Targeting <i>BRAF</i> WT metastatic melanomas: Identifying ERBB4 mutations as biomarkers for novel combinatorial treatment strategies
Abstract A21: Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene
Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics
Targeting BRAF WT metastatic melanomas: Identifying ERBB4 mutant alleles as biomarkers for novel combinatorial treatment strategies
Abstract 2144: Mutations in<i>ERBB4</i>may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway
Abstract 2144: Mutations in <i>ERBB4</i> may account for clinical resistance of melanomas to inhibitors of the RAS/RAF/MEK/MAPK pathway
Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery
Estrogen receptor-α, progesterone receptor, and c-<i>erb</i>B/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer
Abstract 1245: Screening methodologies for the discovery of small molecule melanoma therapeutics targeted at the ErbB4 receptor tyrosine kinase
Abstract 1353: Validation and implementation of screens for partial agonists and antagonists of the ErbB4/HER4 receptor tyrosine kinase: Targeted melanona drug discovery
Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells
Abstract B17: A high-throughput screening process for the discovery of melanoma chemotherapeutics targeted at the ErbB4 receptor tyrosine kinase
Epiregulin: Roles in normal physiology and cancer
Team-Based Learning in US Colleges and Schools of Pharmacy
Autocrine-Derived Epidermal Growth Factor Receptor Ligands Contribute to Recruitment of Tumor-Associated Macrophage and Growth of Basal Breast Cancer Cells In Vivo
EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling